毕得医药1月26日获融资买入477.40万元，融资余额3326.79万元

Group 1 - The core business of Shanghai Bid Pharma focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [2] - As of September 30, 2025, Bid Pharma achieved operating revenue of 979 million yuan, a year-on-year increase of 20.67%, and a net profit attributable to shareholders of 120 million yuan, up 42.79% year-on-year [2] - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3] Group 2 - As of January 26, 2025, Bid Pharma's financing balance is 33.27 million yuan, accounting for 1.09% of its market capitalization, which is below the 30th percentile level over the past year [1] - On January 26, 2025, Bid Pharma had a net financing buy of -347,900 yuan, with a financing buy of 477,400 yuan and a financing repayment of 512,190 yuan [1] - The company has a total of 3,493 shareholders as of September 30, 2025, a decrease of 7.64% from the previous period, while the average circulating shares per person increased by 8.27% to 12,377 shares [2][3]